PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
5.43%
Growth of 5.43% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
7.10%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 0.77%. Jim Chanos would check for structural cost disadvantages.
-1.29%
Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
-6.38%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.45%
Other expenses change of 67.45% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
3.57%
Operating expenses growth 1.25-1.5x Medical - Pharmaceuticals median of 2.58%. Guy Spier would scrutinize spending.
6.53%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 2.63%. Jim Chanos would check for waste.
-7.14%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
63.03%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.78%. Jim Chanos would check for overinvestment.
1.44%
EBITDA change of 1.44% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-3.78%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-18.28%
Operating income decline while Medical - Pharmaceuticals median is -2.30%. Seth Klarman would investigate causes.
-22.49%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
200.00%
Other expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 9.24%. Jim Chanos would check for issues.
1.47%
Income change of 1.47% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-3.76%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-4.29%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
5.98%
Income change of 5.98% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
0.52%
Margin change of 0.52% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
5.99%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 1.33%. Joel Greenblatt would investigate advantages.
5.99%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 1.00%. Joel Greenblatt would investigate advantages.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.24%. Seth Klarman would investigate strategy.
No Data
No Data available this quarter, please select a different quarter.
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09